Milestone Pharmaceuticals Expands Team with Equity Options
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) has made an exciting announcement, revealing that the company has granted equity awards in the form of 94,000 options. This decision, made to enhance employee recruitment, aligns with their 2021 Inducement Plan, which was previously endorsed by both the Compensation Committee and the Board of Directors.
Details of the Equity Grants
The equity awards, providing the opportunity to purchase common shares, were granted on March 3, 2025, at an exercise price of $1.65 per share. This price reflects the closing value of Milestone’s shares on the day of the grant. The awarded shares will have a structured vesting schedule over four years, with 25% becoming accessible on the first anniversary of the commencement date, followed by a series of monthly installments.
Terms and Conditions of the Options
Those who received the option grants must meet certain continuous service requirements to maintain their eligibility for each vesting date. Furthermore, these options are issued under the framework of the Inducement Plan, ensuring compliance with the terms outlined in standard grant agreements established by the company.
Purpose and Compliance with Nasdaq Requirements
This grant serves as a significant incentive for new employees joining Milestone Pharmaceuticals, adhering to the Nasdaq Listing Rule 5635(c)(4). Such grants are exclusively designed for individuals who were not previous employees or had a bona fide period of non-employment, ensuring they have an enticing pathway into the company.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is on the forefront of cardiovascular innovation, dedicated to creating and commercializing solutions that greatly enhance the lives of individuals with complex heart conditions. By honing in on the unmet needs of patients, Milestone is revolutionizing treatment approaches that empower patients in managing their health.
One of their standout products is etripamil, a pioneering calcium channel blocker nasal spray. This innovative treatment is currently under investigation for self-administration by patients, aiding in the management of symptomatic episodic attacks associated with PSVT and AFib-RVR. Through their research and development, Milestone is committed to improving patient experiences and outcomes in the world of cardiovascular care.
For further inquiries, feel free to reach out to:
Kim Fox, Vice President, Communications
kfox@milestonepharma.com
704-803-9295
Frequently Asked Questions
What are the equity options granted by Milestone Pharmaceuticals?
Milestone Pharmaceuticals has granted a total of 94,000 equity options to new employees, allowing them to purchase company shares at a specified price.
What is the significance of the Nasdaq Listing Rule 5635(c)(4)?
This rule allows for grants of equity awards as a material inducement to attract new employees, ensuring compliance with exchange standards.
How does the vesting schedule for the options work?
The options will vest over four years, with a quarter of the shares vesting on the first anniversary, followed by monthly increments for the remaining shares.
What is etripamil?
Etripamil is Milestone's leading investigational product, a nasal spray designed to be self-administered by patients for managing certain heart-related conditions.
Who can be contacted for more information about Milestone Pharmaceuticals?
Interested parties can contact Kim Fox, the Vice President of Communications, at kfox@milestonepharma.com or call 704-803-9295 for any inquiries.
